Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Survival Benefit in Renal Transplantation Despite High Comorbidity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Transplantation With Livers From Deceased Donors Older Than 75 Years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Heart Rate Reserve on Exercise Capacity in Patients Treated with a Continuous Left Ventricular Assist Device

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Performance of Prognostic Risk Scores in Heart Failure Patients: Do Sex Differences Exist?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Finn Gustafsson
  • Arne K Andreassen
  • Bert Andersson
  • Hans Eiskjær
  • Göran Rådegran
  • Einar Gude
  • Kjell Jansson
  • Dag Solbu
  • Kristjan Karason
  • Satish Arora
  • Göran Dellgren
  • Lars Gullestad
  • SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators
Vis graf over relationer

BACKGROUND: A calcineurin inhibitor (CNI)-free immunosuppressive regimen has been demonstrated to improve renal function early after heart transplantation, but long-term outcome of such a strategy has not been well described.

METHODS: In the randomized SCHEDULE trial, de novo heart transplant recipients received (1) everolimus with reduced-exposure CNI (cyclosporine) followed by CNI withdrawal at week 7-11 posttransplant or (2) standard-exposure cyclosporine, both with mycophenolate mofetil and corticosteroids; 95/115 randomized patients were followed up at 5-7 years posttransplant.

RESULTS: Mean measured glomerular filtration rate was 74.7 mL/min and 62.4 mL/min with everolimus and CNI, respectively. The mean difference was in favor of everolimus by 11.8 mL/min in the intent-to-treat population (P = 0.004) and 17.2 mL/min in the per protocol population (n = 75; P < 0.001). From transplantation to last follow-up, the incidence of biopsy-proven acute rejection (BPAR) was 77% (37/48) and 66% (31/47) (P = 0.23) with treated BPAR in 50% and 23% (P < 0.01) in the everolimus and CNI groups, respectively; no episode led to hemodynamic compromise. Coronary allograft vasculopathy (CAV) assessed by coronary intravascular ultrasound was present in 53% (19/36) and 74% (26/35) of everolimus- and CNI-treated patients, respectively (P = 0.037). Graft dimensions and function were similar between the groups. Late adverse events were comparable.

CONCLUSIONS: These results suggest that de novo heart transplant patients randomized to everolimus and low-dose CNI followed by CNI-free therapy maintain significantly better long-term renal function as well as significantly reduced CAV than patients randomized to standard CNI treatment. Increased BPAR in the everolimus group during year 1 did not impair long-term graft function.

OriginalsprogEngelsk
TidsskriftTransplantation
Vol/bind104
Udgave nummer1
Sider (fra-til)154-164
Antal sider11
ISSN0041-1337
DOI
StatusUdgivet - 1 jan. 2020

ID: 57664193